Viskase Holdings, Inc 10-Q for FY2026 Q2

Viskase Holdings, Inc. (VISK)

10-Q 2026-08-03 For: 2026-06-30

Added on August 03, 2026

About this 10-Q

Viskase Holdings, Inc filed this 10-Q on August 3, 2026, covering the quarter ended June 30, 2026 (FY2026 Q2).

Headline figures

Quarter ended June 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue: $90.13M; down 7.3% from $97.28M a year earlier
Net loss: $5.06M; compared with a net loss of $20.25M a year earlier
Diluted EPS: -$0.35; compared with -$3.74 a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


Delaware	22-2372868
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

333 East Butterfield Road, Suite 400, Lombard, Illinois	60148
(Address of principal executive offices)	(Zip Code)

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A


Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐


		Page
	PART I - FINANCIAL INFORMATION	3
Item 1.	Financial Statements (Unaudited)	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	41
Item 4.	Controls and Procedures	41

	PART II – OTHER INFORMATION	41

Item 1.	Legal Proceedings	41
Item 1A.	Risk Factors	41
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	42
Item 3.	Defaults Upon Senior Securities	42
Item 4.	Mine Safety Disclosures	42
Item 5.	Other Information	42
Item 6.	Exhibits	42
Signatures		44


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


		June 30,			December 31,
		2026			2025
		(Unaudited)			(Audited)
ASSETS

Current assets:
Cash and cash equivalents		$	7,911		$	9,217
Receivables, net			67,385			60,182
Inventories, net			105,296			96,755
Other current assets			46,745			42,494
Total current assets			227,337			208,648

Property, plant and equipment			493,194			482,326
Less accumulated depreciation			(345,541)			(341,022)
Property, plant and equipment, net			147,653			141,304

Right of use assets			18,094			19,946
Other assets, net			9,821			9,842
Intangible assets, net			12,620			13,401
Goodwill			3,049			3,131
Deferred tax asset			5,909			5,870
Total Assets		$	424,483		$	402,142

LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY
Current liabilities:
Short-term debt		$	54,468		$	141,774
Accounts payable			39,424			44,342
Accrued liabilities			25,495			24,282
Short-term lease liabilities			4,243			4,119
Total current liabilities			123,630			214,517

Long-term debt, net of current maturities			74,929			—
Long-term liabilities:
Accrued employee benefits			22,609			23,597
Deferred income taxes			1,470			1,557
Long-term lease liabilities			16,200			18,111

Mezzanine equity:
Series C preferred stock - $0.01 par value, 3,000,000 shares authorized, 384 and 0 issued and outstanding (liquidation value $1,129 and $0 per share) at June 30, 2026 and December 31, 2025, respectively			433			—

Stockholders’ equity:
Common stock, $0.01 par value; 170,000,000 shares authorized, 14,371,173 shares issued and 14,331,620 shares outstanding at June 30, 2026 and 170,000,000 shares authorized 6,651,652 shares issued and 6,612,099 shares outstanding at December 31, 2025			143			66
Paid in capital			267,959			213,019
Retained earnings			(23,632)			(11,881)
Accumulated other comprehensive loss			(57,670)			(55,361)
Total Viskase stockholders’ equity			186,800			145,843
Deficit attributable to non-controlling interest			(1,587)			(1,483)
Total stockholders’ equity			185,213			144,360
Total Liabilities, Mezzanine Equity, and Stockholders’ Equity		$	424,483		$	402,142


	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	June 30,		June 30,		June 30,		June 30,
	2026		2025		2026		2025

NET SALES	$	90,131	$	97,279	$	176,668	$	191,467
Cost of sales		79,033		85,645		156,570		165,427

GROSS MARGIN		11,098		11,634		20,098		26,040

Selling, general and administrative		12,149		12,929		24,583		24,624
Amortization of intangibles		535		388		1,071		750
Asset impairment expense		226		—		226		12,100
Restructuring expense		203		947		566		5,597

OPERATING LOSS		(2,015)		(2,630)		(6,348)		(17,031)
Interest expense, net		2,704		2,837		5,528		5,597
Other expense (income), net		109		438		(1,074)		(1,717)

LOSS BEFORE INCOME TAXES		(4,828)		(5,905)		(10,802)		(20,911)
Income tax provision		305		14,353		1,053		12,941

NET LOSS		(5,133)		(20,258)		(11,855)		(33,852)

Less: net loss attributable to noncontrolling interests	$	(71)	$	(12)	$	(104)	$	(21)

Net loss attributable to Viskase Holdings, Inc	$	(5,062)	$	(20,246)	$	(11,751)	$	(33,831)

WEIGHTED AVERAGE COMMON STOCK
- BASIC AND DILUTED		14,331,620		5,419,340		11,149,115		5,273,964

PER SHARE AMOUNTS:
EARNINGS PER SHARE
- BASIC AND DILUTED	$	(0.35)	$	(3.74)	$	(1.05)	$	(6.41)


	Mezzanine	Mezzanine
	Equity	Equity		Common									Accumulated		Total
	Series C	Series C		stock									other		Viskase		Non-		Total
	Preferred	Preferred		Issued	Common		Paid in		Treasury		Retained		comprehensive		stockholders’		controlling		stockholders’
	Stock (Shares)	Stock		(Shares)	stock		capital		stock		earnings		loss		equity		Interest		equity
Balance January 1, 2025 (as previously reported)	—		—	103,190,665	$	1,040	$	182,343	$	(298)	$	53,610	$	(65,386)	$	171,309	$	(1,321)	$	169,988
Retroactive application of Merger	—		—	(98,122,166)		(989)		691		298		—		—		—		—		—
Balances at January 1, 2025 effect of reverse acquisition (refer to Note 2)	—		—	5,068,499		51		183,034		—		53,610		(65,386)		171,309		(1,321)		169,988

Net (loss)	—		—	—		—		—		—		(13,585)		—		(13,585)		(9)		(13,594)
Foreign currency translation adjustment	—		—	—		—		—		—		—		2,157		2,157		—		2,157
Pension liability adjustment, net of tax	—		—	—		—		—		—		—		99		99		—		99
Private placement of common stock	—		—	350,841		4		14,996		—		—		—		15,000		—		15,000
Balance March 31, 2025	—		—	5,419,340	$	55	$	198,030	$	—	$	40,025	$	(63,130)	$	174,980	$	(1,330)		173,650

Net (loss)	—		—	—		—		—		—		(20,244)		—		(20,244)		(12)		(20,258)
Foreign currency translation adjustment	—		—	—		—		—		—		—		5,237		5,237		—		5,237
Pension liability adjustment, net of tax	—		—	—		—		—		—		—		1,187		1,187		—		1,187
Balance June 30, 2025	—		—	5,419,340	$	55	$	198,030	$	—	$	19,781	$	(56,706)	$	161,160	$	(1,342)	$	159,816


Shares held by legacy Enzon common stockholders following Reverse Stock Split (prior to IEH Share Exchange and Series C Exchange Offer)		742,005
Shares held by IEH Parties subsequent to IEH Share Exchange		5,658,396
Shares held by non-IEH Parties subsequent to Series C Exchange Offer		48,832
Subtotal - Equity consideration issued for acquisition		6,449,233
Exchange of shares of Viskase Companies, Inc. common stock for shares of Viskase Holdings, Inc. common stock		7,882,387
Total shares of Viskase Holdings, Inc. common stock		14,331,620


Cash and cash equivalents	$	40,854
Prepaid expenses and other current assets		160
Accrued expenses and other current liabilities		(565)
Net assets acquired	$	40,449


		Six months
		ended
		June 30, 2026
Prepaids and other current assets acquired in connection with the Merger		$	160
Other liabilities assumed in connection with the Merger		$	565
Series C preferred stock historically outstanding at Enzon that remained outstanding following the Merger		$	433


(thousands)		June 30, 2026			December 31, 2025
Accounts receivable, gross		$	70,336		$	63,123
Less allowance for credit losses			(2,951)			(2,941)
Receivables, net		$	67,385		$	60,182


		U.S. Pension Benefits
		Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
		June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025
Component of net period benefit cost
Service cost		$	—		$	—		$	—		$	—
Interest cost			1,170			1,215			2,340			2,433
Expected return on plan assets			(1,229)			(1,192)			(2,457)			(2,383)
Amortization of prior service cost			—			—			—			—
Amortization of actuarial loss			6			22			12			44
		$	(53)		$	45		$	(105)		$	94

		Non U.S. Pension Benefits
		Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
		June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025
Component of net period benefit cost
Service cost		$	95		$	81		$	192		$	162
Interest cost			207			171			410			342
Expected return on plan assets			(5)			(5)			(12)			(11)
Amortization of prior service cost			1			—			2			—
Amortization of actuarial loss			(105)			(21)			(211)			(42)
		$	193		$	226		$	381		$	451


	Six Months Ended		Six Months Ended
	June 30,		June 30,
	2026		2025

Cash flows from operating activities:
Net loss	$	(11,855)	$	(33,852)

Adjustments to reconcile net loss to net cash
(used in) provided by operating activities:
Depreciation and amortization		8,648		10,290
Amortization of deferred financing fees		842		322
Deferred income taxes		103		—
Loss on impairment of assets		226		12,100

Changes in operating assets and liabilities:
Receivables		(8,290)		4,462
Inventories		(10,421)		4,848
Other current assets		(4,850)		2,344
Other assets		(237)		11,363
Accounts payable		(3,129)		(5,434)
Accrued liabilities		1,772		(395)
Accrued employee benefits		(338)		(1,503)
Other		9		(2,171)
Total adjustments		(15,665)		36,226

Net cash (used in) provided by operating activities		(27,520)		2,373

Cash flows from investing activities:
Capital expenditures		(16,682)		(16,342)
Net cash used in investing activities		(16,682)		(16,342)

Cash flows from financing activities:
Cash acquired in connection with reverse recapitalization		40,855		—
Deferred financing costs		(1,958)		(300)
Issuance of common stock		15,000		15,000
Repayment of short-term debt		(11,547)		(5,625)
Proceeds from long-term debt		647		7,758
Net cash provided by financing activities		42,997		16,833


(thousands)		June 30, 2026			December 31, 2025
Raw materials		$	27,603		$	27,141
Work in process			43,910			38,106
Finished products			33,783			31,508
Total inventories, net		$	105,296		$	96,755


(thousands)		June 30, 2026			December 31, 2025
Land and improvements		$	1,932		$	1,880
Buildings and improvements			54,325			55,331
Machinery and equipment			352,266			354,178
Furniture and fixtures			28,946			28,981
Construction in progress			55,725			41,956
Total property plant and equipment		$	493,194		$	482,326


(thousands)		June 30, 2026			December 31, 2025
Land and improvements		$	647		$	533
Buildings and improvements			32,042			31,691
Machinery and equipment			296,771			292,736
Furniture and fixtures			16,081			16,062
Total accumulated depreciation		$	345,541		$	341,022


	Three Months Ended June 30, 2026
	North		South						Elimination
	America		America		EMEA		Asia		and other		Consolidated
Sales from external customers	$	36,234	$	11,040	$	34,332	$	8,525	$	—	$	90,131
Intersegment net sales		5,141		—		15,706		—		—		20,847
		41,375		11,040		50,038		8,525		—		110,978

Reconciliation of revenue
Elimination of intersegment sales										(20,847)		(20,847)
Total consolidated net sales											$	90,131

Cost of sales		(37,936)		(10,300)		(43,448)		(8,200)		20,851		(79,033)
Selling and marketing		(1,053)		(417)		(952)		(57)		—		(2,479)
General and administrative		(5,373)		(476)		(3,041)		(132)		—		(9,022)
Research and development		(488)		(15)		(116)		(30)		—		(649)
Amortization of intangibles		(28)		(125)		(381)		—		—		(535)
Asset impairment charge		(226)		—		—		—		—		(226)
Restructuring expense and related expense		(203)		—		—		—		—		(203)
Segment operating income		(3,932)		(293)		2,100		106		4		(2,015)

Interest expense, net												2,704
Other (expense) income, net												109
Net (loss) income before income taxes											$	(4,828)


	Three Months Ended June 30, 2025
	North		South						Elimination
	America		America		EMEA		Asia		and other		Consolidated
Sales from external customers	$	41,209	$	11,596	$	34,115	$	10,359	$	—	$	97,279
Intersegment net sales		5,794		7		10,488		1,549		—		17,838
		47,003		11,603		44,603		11,908		—		115,117

Reconciliation of revenue
Elimination of intersegment sales										(17,838)		(17,838)
Total consolidated net sales											$	97,279

Cost of sales		(40,801)		(10,447)		(41,469)		(10,777)		17,849		(85,645)
Selling and marketing		(1,108)		(255)		(860)		(62)		—		(2,285)
General and administrative		(6,421)		(557)		(2,816)		(182)		—		(9,976)
Research and development		(536)		(10)		(107)		(15)		—		(668)
Amortization of intangibles		(25)		—		(363)		—		—		(388)
Asset impairment charge		—		—		—		—		—		—
Restructuring expense and related expense		(821)		(126)		—		—		—		(947)
Segment operating income		(2,709)		208		(1,012)		872		11		(2,630)

Interest expense, net												(2,837)
Other (expense) income, net												(438)
Net (loss) income before income taxes											$	(5,905)


		Six Months Ended June 30, 2026
		North America			South America			EMEA			Asia			Elimination			Consolidated
Sales from external customers		$	69,609		$	22,427		$	68,231		$	16,401		$	—		$	176,668
Intersegment net sales			8,257			—			33,431			4			—			41,692
			77,866			22,427			101,662			16,405			—			218,360

Reconciliation of revenue
Elimination of intersegment sales															(41,692)			(41,692)
Total consolidated net sales																	$	176,668

Cost of sales			(72,521)			(20,518)			(90,120)			(15,103)			41,692			(156,570)
Selling and marketing			(2,068)			(849)			(1,943)			(123)			—			(4,983)
General and administrative			(11,287)			(995)			(5,742)			(370)			—			(18,394)
Research and development			(877)			(26)			(244)			(60)			—			(1,207)
Amortization of intangibles			(57)			(245)			(768)			—			—			(1,071)
Asset impairment charge			(226)			—			—			—			—			(226)
Restructuring expense and related expense			(566)			—			—			—			—			(566)
Segment operating income			(9,736)			(206)			2,845			749			—			(6,348)

Interest expense, net																		5,528
Other (expense) income, net																		(1,074)
Net (loss) income before income taxes																	$	(10,802)


		Six Months Ended June 30, 2025
														Elimination
		North America			South America			EMEA			Asia			and other			Consolidated
Sales from external customers		$	84,694		$	22,918		$	64,131		$	19,724		$	—		$	191,467
Intersegment net sales			15,620			80			21,532			1,549			—			38,781
			100,314			22,998			85,663			21,273			—			230,248

Reconciliation of revenue
Elimination of intersegment sales															(38,781)			(38,781)
Total consolidated net sales																	$	191,467

Cost of sales			(88,179)			(20,612)			(76,214)			(19,286)			38,864			(165,427)
Selling and marketing			(2,216)			(630)			(1,698)			(100)			—			(4,644)
General and administrative			(11,606)			(1,255)			(5,526)			(391)			—			(18,778)
Research and development			(1,068)			(21)			(209)			(30)			—			(1,328)
Amortization of intangibles			(53)			—			(697)			—			—			(750)
Asset impairment charge			(12,100)			—			—			—			—			(12,100)
Restructuring expense and related expense			(5,471)			—			—			—			—			(5,597)
Segment operating income			(20,379)			480			1,319			1,466			83			(17,031)

Interest expense, net																		(5,597)
Other income (expense), net																		1,717
Net (loss) income before income taxes																	$	(20,911)


	Before-		Tax (Expense)		Net-of-
	Tax Amount		or Benefit		Tax Amount
Balance at June 30, 2026
Foreign currency translation adjustments	$	(1,916)	$	—	$	(1,916)
Pension liability adjustments		(393)		—		(393)
Total other comprehensive (loss) income	$	(2,309)	$	—	$	(2,309)


	Accrued		Translation
	Employee Benefits		Adjustments		Total
Balance at December 31, 2024	$	(20,958)	$	(44,428)	$	(65,386)
Other comprehensive income (loss) before
reclassifications		—		2,157		2,157
Reclassifications from accumulated other
comprehensive loss to earnings		99		—		99
Balance at March 31, 2025	$	(20,859)	$	(42,271)	$	(63,130)

Other comprehensive income (loss) before
reclassifications		—		5,237		5,237
Reclassifications from accumulated other
comprehensive loss to earnings		1,187		—		1,187
Balance at June 30, 2025	$	(19,672)	$	(37,034)	$	(56,706)


		Three Months			Three Months			Six Months			Six Months
		Ended			Ended			Ended			Ended
		June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025
Net sales		$	139		$	124		$	341		$	358
Cost of sales			188			149			400			361
Gross margin			(49)			(25)			(59)			(3)

Selling, general and administrative			11			9			26			23
Asset impairment			—			—			—			—

Operating loss			(60)			(34)			(85)			(26)

Other expense			11			(9)			19			(17)
Loss before income taxes			(71)			(25)			(104)			(43)

Income tax expense			—			—			—			—

Net loss		$	(71)		$	(25)		$	(104)		$	(43)


(in thousands)	June 30, 2026		December 31, 2025
Beginning balance	$	153	$	—
Provision		566		7,054
Payments		(719)		(6,901)
Translation		—		—
Ending balance	$	—	$	153


		Six			Six
		Months Ended			Months Ended
		June 30,			June 30,
		2026			2025
Cash restructuring charges:
Severance and other personnel costs		$	—		$	5,597
Transfer and disposal costs and professional fees			566			—
Total cash charges			566			5,597
Non-cash charges:
Write-offs of inventory due to restructuring plan			—			12,100
Total non-cash charges			—			12,100
Total		$	566		$	17,697


	Net Sales
													Corporate and
	North America			South America			EMEA			Asia			Other		Consolidated
Three months Ended June 30, 2026	$	41,375		$	11,040		$	50,038		$	8,525		$	—	$	110,978
Three months Ended June 30, 2025		47,003			11,603			44,603			11,908			—		115,117
Change - $		(5,628)			(563)			5,435			(3,383)			—		(4,139)
Change - %		(13.6)	%		(5.1)	%		10.9	%		(39.7)	%		—		(3.7)	%


		Operating (Loss) Income
														Corporate
														and
		North America			South America			EMEA			Asia			Other			Consolidated
Three months Ended June 30, 2026		$	(3,932)		$	(293)		$	2,100		$	106		$	4		$	(2,015)
Three months Ended June 30, 2025			(2,709)			208			(1,012)			872			11			(2,630)
Change -$			(1,223)			(501)			3,112			(766)			—			615
Change - %			31.1	%		171.0	%		148.2	%		(722.6)	%		—			(30.5)	%


Exhibit Number	Description	Reference No.
2.1**	Agreement and Plan of Merger, dated as of June 20, 2025, by and between Enzon Pharmaceuticals, Inc., EPSC Acquisition Corp. and Viskase Companies, Inc.	13
3.1	Amended and Restated Certificate of Incorporation dated May 18, 2006, together with that Certificate of Amendment to the Amended and Restated Certificate of Incorporation dated July 13, 2010.	1
3.2	Second Amended and Restated By-Laws effective March 11, 2011, as amended by Amendment No. 1 to the Second Amended and Restated By-Laws effective February 15, 2013.	2
3.3	Certificate of Designation of Series A-1 Junior Participating Preferred Stock of Enzon Pharmaceuticals, Inc. filed with the Secretary of State of the State of Delaware on August 14, 2020.	3
3.4	Certificate of Designation of Series C Non-Convertible Redeemable Preferred Stock of Enzon Pharmaceuticals, Inc., filed with the Secretary of State of the State of Delaware on September 21, 2020.	4
3.5	First Amendment to the Second Amended and Restated By-Laws, effective February 24, 2022.	5
3.6	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Enzon Pharmaceuticals, Inc. dated March 24, 2026.	11
3.7	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Enzon Pharmaceuticals, Inc. dated March 20, 2026.	11
3.8	Certificate of Amendment, dated as of March 26, 2026.	12
3.9	Certificate of Elimination of Series A-1 Junior Participating Preferred Stock, dated as of March 26, 2026.	12
3.10	Certificate of Designations of Series A-2 Junior Participating Preferred Stock of Viskase Holdings, Inc., filed with the Secretary of State of the State of Delaware on May 5, 2026.	8
4.1	Seventh Amendment to the Section 382 Rights Agreement, dated as of January 30, 2026, by and between Enzon Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company.	6
4.2	Eighth Amendment to the Section 382 Rights Agreement, dated as of February 27, 2026, by and between Enzon Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company.	7
4.3	Ninth Amendment to the Section 382 Rights Agreement, dated as of March 10, 2026, by and between Enzon Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company.	9
4.4	Tenth Amendment to the Section 382 Rights Agreement, dated as of March 18, 2026, by and between Enzon Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company.	10
4.5	Eleventh Amendment to the Section 382 Rights Agreement, dated as of March 23, 2026, by and between Enzon Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company.	11

4.6	Section 382 Rights Agreement, dated as of May 5, 2026, by and between Viskase Holdings, Inc. and Continental Stock Transfer & Trust Company, which includes the Form of Certificate of Designations as Exhibit A thereto, the Form of Rights Certificate as Exhibit B thereto, and the Form of Summary of Rights as Exhibit C thereto.	8
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1	Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
32.2	Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.INS	Inline XBRL Instance Document	+
101.SCH	Inline XBRL Taxonomy Extension Schema Document	+
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	+
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	+
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	+
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	+
104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).	+


	(1)	Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, filed on August 9, 2010.

	(2)	Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 18, 2013.

	(3)	Current Report on Form 8-K filed on August 14, 2020.

	(4)	Current Report on Form 8-K filed on September 23, 2020.

	(5)	Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 25, 2022.

	(6)	Current Report on Form 8-K filed on January 30, 2026.

	(7)	Current Report on Form 8-K filed on February 27, 2026.

	(8)	Current Report on Form 8-K filed on May 5, 2026.

	(9)	Current Report on Form 8-K filed on March 11, 2026.

	(10)	Current Report on Form 8-K filed on March 18, 2026.

	(11)	Current Report on Form 8-K filed on March 24, 2026.

	(12)	Current Report on Form 8-K filed on March 26, 2026.

	(13)	Current Report on Form 8-K filed with the SEC on June 23, 2025.

	VISKASE HOLDINGS, INC.
	(Registrant)


Dated: August 3, 2026	/s/ Thomas D. Davis
	Thomas D. Davis
	Chief Executive Officer
	(Principal Executive Officer)

Dated: August 3, 2026	/s/ Michael Blecic
	Michael Blecic Chief Financial Officer, Vice President, Chief Accounting Officer, Treasurer
	(Principal Financial Officer and Principal Accounting Officer)


August 3, 2026	/s/ Thomas D. Davis
	Thomas D. Davis
	Chief Executive Officer
	(Principal Executive Officer)


August 3, 2026	/s/ Michael Blecic
	Michael Blecic
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)